The global protein therapeutics market was valued at USD 284.5 billion in 2021 and it is predicted to surpass around USD 566.82 billion by 2030 with a CAGR of 7.96% from 2022 to 2030.
Key Findings of the Study
Therapeutic proteins are the medicines that are genetically engineered versions of naturally occurring human proteins. They can be used to replace a protein that is abnormal or deficient in a specific disease. They can also supplement supply of a beneficial protein, which can help mitigate effects of disease or chemotherapy. Genetically engineered proteins can be designed to closely resemble natural proteins they replace or they can be enhanced by addition of sugars or other molecules that extend the protein's activity duration.
Therapeutic protein drugs are a type of medicine that are used to treat a variety of diseases such as cancer, metabolic, immunological, hematological, hormonal, genetic, infectious diseases, and others. These drugs have the potential to significantly improve human health. In principle, protein therapy is similar to gene therapy; which involves protein delivery in specific amounts to the body to facilitate precise functioning of different glands and other organs in the body
Growth of the protein therapeutics market is majorly driven by rise in prevalence of chronic diseases and development of plasma-derived therapies. Increase in prevalence of various diseases such as cancer, metabolic disorders, genetic disorders, and immunological diseases are expected to propel demand for protein therapeutics. In addition, according to the World Health Organization (WHO), cancer is a leading cause of death worldwide, and cancer cases are expected to increase significantly in the future. Thus, rise in prevalence of cancer is anticipated to drive the protein therapeutics market.
In addition, rise in proteomics research has further led to rise in the market growth. Protein microarray allows classification of proteins in a parallel and high-throughput way. The possibility of performing numerous assays in one small plate saves time of researchers and curbs the experiment cost. Growth in proteomic research is expected to lead to an increase in emergence of new protein drugs, which can further be used for treatment of various diseases.
However, high production costs required for developing as well as manufacturing protein-based therapeutics is expected to restrain growth of the market. Conversely, considerable rise in healthcare expenditure globally has led to the protein therapeutics market growth. Emerging economies of Asia-Pacific and LAMEA possess high potential for protein therapeutics. Growth in awareness regarding chronic diseases and use of proteins for treatment of these diseases has resulted in regulatory authorities in this region to take key decisions to improve legislations of protein therapeutics. Increase in geriatric population, growth in number of chronic diseases, and high requirement for protein therapeutics are expected to drive demand for these products over the next few years. In addition, emerging nations need to focus on cost-effectiveness and scalability to cater to the needs of the rising patient pool.
Scope of The Report
|Market Size in 2021||USD 284.5 billion|
|Revenue Forecast by 2030||USD 566.82 billion|
|Growth rate from 2022 to 2030||CAGR of 7.96%|
|Forecast Period||2022 to 2030|
|Companies Covered||Abbott Laboratories; Amgen Inc.; Baxter International Inc.; Eli Lilly And Company; F. Hoffmann La Roche Ltd; Johnson and Johnson (Janssen Pharmaceuticals); Merck and Co., Inc.; Novo Nordisk AS; Pfizer Inc.; Sanofi|
What is the Impact of COVID-19 Pandemic on the Protein Therapeutics Market?
In addition, the COVID-19 outbreak is anticipated to have a positive impact on the protein therapeutics market. A huge number of clinics and hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. Non-essential procedures took a potential backlog, owing to rapid rise in COVID-19 cases. The lockdown led to disruption of manufacturing and transportation of healthcare essentials. However, diagnosis and treatment of COVID-19 and other diseases increased significantly during the pandemic, thus demand for protein based therapeutic drugs was increased.
Protein Therapeutics Market Segmentation
The protein therapeutics market is segmented into product, application, and region. On the basis of product, it is classified into monoclonal antibodies, insulin, fusion protein, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. On the basis of application, it is classified into metabolic disorders, immunologic disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
On the basis of product, the monoclonal antibodies segment dominated the market in 2020, and is expected to remain dominant during the forecast period, owing to its wide range of availability, importance and applicability of these products in the treatment of different chronic disorders.
By application, the metabolic disorders segment dominated the market in 2020, and is expected to remain dominant during the forecast period, owing to requirement for quality drugs and versatile therapies for disease treatment, especially diabetes, which is expected to boost the growth of this segment.
North America exhibited the global protein therapeutics market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of chronic diseases, adoption of technologically advanced treatments, presence of key players, and rise in healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in R&D activities, increase in disposable incomes, and improvement in patient awareness toward protein therapeutics. Moreover, India and China are expected to grow at high CAGR in the Asia-Pacific protein therapeutics market.
Key Benefits for Stakeholders
Key Market Players